- Home
- CBAT vs CLSD Comparison
CBAT vs CLSD Comparison
Compare CBAT & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- CLSD
- Stock Information
- Founded
- CBAT 1999
- CLSD 2011
- Country
- CBAT China
- CLSD United States
- Employees
- CBAT N/A
- CLSD N/A
- Industry
- CBAT Industrial Machinery/Components
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CBAT Miscellaneous
- CLSD Health Care
- Exchange
- CBAT Nasdaq
- CLSD Nasdaq
- Market Cap
- CBAT 78.7M
- CLSD 74.3M
- IPO Year
- CBAT N/A
- CLSD 2016
- Fundamental
- Price
- CBAT $0.89
- CLSD $0.93
- Analyst Decision
- CBAT
- CLSD Strong Buy
- Analyst Count
- CBAT 0
- CLSD 6
- Target Price
- CBAT N/A
- CLSD $5.33
- AVG Volume (30 Days)
- CBAT 1.2M
- CLSD 301.0K
- Earning Date
- CBAT 03-14-2025
- CLSD 03-11-2025
- Dividend Yield
- CBAT N/A
- CLSD N/A
- EPS Growth
- CBAT N/A
- CLSD N/A
- EPS
- CBAT 0.12
- CLSD N/A
- Revenue
- CBAT $207,423,403.00
- CLSD $7,703,000.00
- Revenue This Year
- CBAT $0.46
- CLSD N/A
- Revenue Next Year
- CBAT $13.78
- CLSD $91.87
- P/E Ratio
- CBAT $7.38
- CLSD N/A
- Revenue Growth
- CBAT 2.32
- CLSD 248.39
- 52 Week Low
- CBAT $0.77
- CLSD $0.80
- 52 Week High
- CBAT $2.08
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- CBAT 45.53
- CLSD 42.76
- Support Level
- CBAT $0.85
- CLSD $0.90
- Resistance Level
- CBAT $1.11
- CLSD $0.97
- Average True Range (ATR)
- CBAT 0.10
- CLSD 0.05
- MACD
- CBAT -0.01
- CLSD 0.00
- Stochastic Oscillator
- CBAT 10.16
- CLSD 24.29
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.